The phase II oral HDACi tucidinostat mitigates the negative prognostic impact of CREBBP/EP300 mutations on DLBCL (ClinicalTrials.gov: NCT02753647) [125,126]. This evidence concerns the gene CREBBP and diffuse large B-cell lymphoma.